Repligen reported $71.08M in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agilent A:US $ 514M 48M
Align Technology ALGN:US $ 191.46M 36.25M
Biomarin Pharmaceutical BMRN:US $ 64.42M 7.75M
Bristol Myers Squibb BMY:US $ 5780M 8M
Bruker BRKR:US $ 107.6M 17.5M
Catalent CTLT:US $ 361M 46M
Charles River Laboratories CRL:US $ 263.83M 39.76M
Danaher DHR:US $ 2757M 20M
Exact Sciences EXAS:US $ -101.13M 28.2M
General Electric GE:US $ 1770M 218M
Henry Schein HSIC:US $ 276M 23M
Illumina ILMN:US $ 124M 151M
IQVIA Holdings Inc IQV:US $ 752M 5M
Mettler Toledo International MTD:US 299.54M 42.2M
Myriad Genetics MYGN:US $ -4.8M 2.9M
Pacific Biosciences Of California PACB:US $ -67.79M 7.24M
Patterson Companies PDCO:US $ 55.02M 38.4M
Peregrine Pharmaceuticals PPHM:US $ 4.34M 1.85M
Perkinelmer PKI:US $ 420.38M 11.6M
Pfizer PFE:US $ 12921M 1739M
Repligen RGEN:US $ 71.08M 1.53M
Thermo Fisher Scientific TMO:US $ 2861M 821M
Waters WAT:US $ 233.88M 5.74M
West Pharmaceutical Services WST:US $ 255.6M 37.4M